Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Pass Below 50 Day Moving Average of $1.64

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRSGet Rating)’s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.64 and traded as low as $1.28. Pieris Pharmaceuticals shares last traded at $1.30, with a volume of 115,635 shares.

Pieris Pharmaceuticals Stock Down 3.0 %

The firm’s 50-day moving average price is $1.64 and its 200 day moving average price is $2.15. The firm has a market cap of $96.73 million, a P/E ratio of -2.24 and a beta of 1.06.

Pieris Pharmaceuticals (NASDAQ:PIRSGet Rating) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $10.47 million. Pieris Pharmaceuticals had a negative return on equity of 82.02% and a negative net margin of 152.68%. On average, equities analysts predict that Pieris Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Pieris Pharmaceuticals

Several institutional investors have recently modified their holdings of PIRS. Woodline Partners LP bought a new position in Pieris Pharmaceuticals in the 4th quarter valued at about $9,313,000. Bank of Montreal Can bought a new position in Pieris Pharmaceuticals in the 2nd quarter valued at about $2,597,000. Great Point Partners LLC grew its position in Pieris Pharmaceuticals by 41.9% in the 1st quarter. Great Point Partners LLC now owns 2,199,076 shares of the biotechnology company’s stock valued at $6,663,000 after buying an additional 649,076 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Pieris Pharmaceuticals in the 1st quarter valued at about $1,263,000. Finally, Lynx1 Capital Management LP bought a new position in Pieris Pharmaceuticals in the 4th quarter valued at about $1,449,000. Institutional investors own 50.17% of the company’s stock.

About Pieris Pharmaceuticals

(Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Featured Stories

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.